Usana Health Sciences Debt-to-EBITDA Ratio Growth & History (USNA)

Usana Health Sciences's debt-to-ebitda ratio was 0.26 for fiscal 2025.

View full Usana Health Sciences company overview

Usana Health Sciences annual debt-to-ebitda ratio history

Usana Health Sciences annual debt-to-ebitda ratio

Fiscal yearPeriod endedDebt-to-EBITDA ratioChangeGrowth
20252026-01-030.260.06+28.02%
20242024-12-280.200.08+70.67%
20232023-12-300.12−0.00−2.50%
20222022-12-310.120.03+27.58%
20212022-01-010.090.05+108.41%
20202021-01-020.05−0.11−71.52%
20192019-12-280.16

Usana Health Sciences debt-to-ebitda ratio trends

Over the last five fiscal years, Usana Health Sciences's debt-to-ebitda ratio increased from 0.05 to 0.26, a change of 0.21. The latest reported quarter, Q1 2026, shows 0.21.

About the metric

What the debt-to-EBITDA ratio means

Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.

Calculation and source

How debt-to-EBITDA is calculated

TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Usana Health Sciences source filings ↗

Community posts

It’s quiet here.

No posts about USNA yet. Start the conversation.

Write the first post